Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

55.15 +0.30 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 Next >
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Bridging the Gap between the Homeless and Society via Futsal
From sanofi-aventis Korea
Via Business Wire
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Sanofi (NASDAQ: SNY) Climbs to New 52-Week High
Via Investor Brand Network
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
From Recludix Pharma, Inc.
Via GlobeNewswire
DarioHealth is an AI-Powered Digital Therapeutics Play
DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.